What Syndax Pharmaceuticals, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 9 |
| Total trades | 0 | 26 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 585,194 |
| Disposed | 0 | 137,201 |
| Net activity | +0 | +447,993 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Metzger Michael A | Chief Executive Officer | Jul 08 | Disclosed 10b5-1 sale · S | −32,375 | $24.24 | −$785K | 484,843 |
| Metzger Michael A | Chief Executive Officer | Jul 08 | Exercise / conversion · M | +32,375 | $6.38 | +$207K | 517,218 |
| Botwood Nicholas A.j. | Head of R&D, CMO | Jun 12 | Disclosed 10b5-1 sale · S | −31,235 | $18.14 | −$567K | 60,885 |
| Botwood Nicholas A.j. | Head of R&D, CMO | Jun 12 | Exercise / conversion · M | +31,235 | $13.82 | +$432K | 92,120 |
| Botwood Nicholas A.j. | Head of R&D, CMO | Jun 11 | Disclosed 10b5-1 sale · S | −34,280 | $18.00 | −$617K | 60,885 |
| Botwood Nicholas A.j. | Head of R&D, CMO | Jun 11 | Exercise / conversion · M | +22,515 | $13.82 | +$311K | 95,165 |
| Goldan Keith A. | Chief Financial Officer | Jun 01 | Open-market sale · S | −1,177 | $18.99 | −$22.4K | 139,252 |
| Metzger Michael A | Chief Executive Officer | Jun 01 | Open-market sale · S | −6,847 | $18.99 | −$130K | 484,843 |
| Goldan Keith A. | Chief Financial Officer | Feb 09 | Open-market sale · S | −3,410 | $21.03 | −$71.7K | 140,429 |
| Metzger Michael A | Chief Executive Officer | Feb 09 | Open-market sale · S | −17,159 | $21.03 | −$361K | 491,690 |
| Metzger Michael A | Chief Executive Officer | Feb 06 | Open-market sale · S | −7,412 | $20.62 | −$153K | 508,849 |
| Goldan Keith A. | Chief Financial Officer | Feb 06 | Open-market sale · S | −2,082 | $20.62 | −$42.9K | 143,839 |
| Rizo Aleksandra | Director | Feb 04 | Grant / award · A | +24,000 | — | — | 49,000 |
| Legault Pierre | Director | Feb 04 | Grant / award · A | +24,000 | — | — | 114,000 |
| Podlesak Dennis | Director | Feb 04 | Grant / award · A | +48,000 | — | — | 239,763 |
| Botwood Nicholas A.j. | Head of R&D, CMO | Feb 04 | Grant / award · A | +36,000 | — | — | 95,165 |
| Botwood Nicholas A.j. | Head of R&D, CMO | Feb 04 | Grant / award · A | +24,000 | — | — | 59,165 |
| Katkin Keith | Director | Feb 04 | Grant / award · A | +24,000 | — | — | 124,000 |
| Huber Martin H. Jr. | Director | Feb 04 | Grant / award · A | +24,000 | — | — | 103,000 |
| Jarrett Jennifer | Director | Feb 04 | Grant / award · A | +24,000 | — | — | 114,000 |
Loading...
